Skip to content
10-Q

Quarterly Report

Reviva Pharmaceuticals Holdings, Inc. RVPH

0001437749-26-016762

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 13.11M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.8M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$8.19M
Short Term Debt Q1 2026 · Mar 31, 2026 $231.27K
Short Term Debt Q1 2026 · Dec 31, 2025 $406.88K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $22.19M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $14.44M
Stockholders Equity Q1 2026 · Mar 31, 2026 $17.44M
Stockholders Equity Q1 2026 · Dec 31, 2025 $8.65M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$4.46M
Stockholders Equity Q1 2026 · Dec 31, 2024 $812.57K
Current Liabilities Q1 2026 · Mar 31, 2026 $6.12M
Current Liabilities Q1 2026 · Dec 31, 2025 $7.28M
Total Liabilities Q1 2026 · Mar 31, 2026 $6.12M
Total Liabilities Q1 2026 · Dec 31, 2025 $7.28M
Current Assets Q1 2026 · Mar 31, 2026 $23.56M
Current Assets Q1 2026 · Dec 31, 2025 $15.1M
Total Assets Q1 2026 · Mar 31, 2026 $23.56M
Total Assets Q1 2026 · Dec 31, 2025 $15.92M
Eps Basic Q1 2026 · Mar 31, 2026 −$0.46
Eps Basic restated Q1 2026 · Mar 31, 2025 −$2.61
Sga Expense Q1 2026 · Mar 31, 2026 $1.84M
Sga Expense Q1 2026 · Mar 31, 2025 $2.42M
Rd Expense Q1 2026 · Mar 31, 2026 $1.44M
Rd Expense Q1 2026 · Mar 31, 2025 $4.11M
Net Income Q1 2026 · Mar 31, 2026 −$3.2M
Net Income Q1 2026 · Mar 31, 2025 −$6.43M
Operating Income Q1 2026 · Mar 31, 2026 −$3.27M
Operating Income Q1 2026 · Mar 31, 2025 −$6.54M